1887

Abstract

The WHO smallpox eradication program was concluded 21 years ago and the non-vaccinated population is now at risk of poxvirus infections, either by contact with monkeypox or through bioterrorism. Since drugs specific against poxvirus infections are limited, neutralizing monoclonal antibodies (mAbs) that are effective may be an important tool in controlling poxvirus infections. To this end, we studied the efficacy of the mAb C3, reactive against the trimeric 14-kDa protein of vaccinia virus (VV) localized in the membrane of the intracellular form of mature virus, for its ability to neutralize VV infection in mice. The results show that prophylactic as well as therapeutic administration of mAb C3 can be an effective means of control of VV replication within the host. The interval of antibody efficacy following a single administration, before and after VV inoculation, has been defined. This study reinforces the notion that neutralizing mAbs should be developed to control health-related human infections by poxviruses.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-83-5-1059
2002-05-01
2024-03-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/83/5/0831059a.html?itemId=/content/journal/jgv/10.1099/0022-1317-83-5-1059&mimeType=html&fmt=ahah

References

  1. Appleyard G., Andrews C. 1974; Neutralizing activities of antisera to poxvirus soluble antigens. Journal of General Virology 23:197–200
    [Google Scholar]
  2. Blasco R., Moss B. 1992; Role of cell-associated enveloped vaccinia virus in cell-to-cell spread. Journal of Virology 66:4170–4179
    [Google Scholar]
  3. Boulter E. A., Appleyard G. 1973; Differences between extracellular and intracellular forms of poxvirus and their implications. Progress in Medical Virology 16:86–108
    [Google Scholar]
  4. Breman J. G. 2000; Monkeypox: an emerging infection for humans?. In Emerging Infections pp 45–67 Edited by Scheld W. M., Craig W. A., Hughes J. M. Washington, DC: American Society for Microbiology;
    [Google Scholar]
  5. Breman J. G., Henderson D. A. 1998; Poxvirus dilemmas – monkeypox, smallpox, and biologic terrorism. New England Journal of Medicine 339:556–559
    [Google Scholar]
  6. Buller R. M., Palumbo G. J. 1991; Poxvirus pathogenesis. Microbiological Reviews 55:80–122
    [Google Scholar]
  7. Buller R. M., Smith G. L., Cremer K., Notkins A. L., Moss B. 1985; Decreased virulence of recombinant vaccinia virus expression vectors is associated with a thymidine kinase-negative phenotype. Nature 317:813–815
    [Google Scholar]
  8. Czerny C.-P., Mahnel H. 1990; Structural and functional analysis of orthopoxvirus epitopes with neutralizing monoclonal antibodies. Journal of General Virology 71:2341–2352
    [Google Scholar]
  9. Dallo S., Rodríguez J. F., Esteban M. 1987; A 14K envelope protein of vaccinia virus with an important role in virus-host cell interactions is altered during virus persistence and determines the plaque size phenotype of the virus. Virology 159:423–432
    [Google Scholar]
  10. Galmiche M. C., Goenaga J., Wittek R., Rindisbacher L. 1999; Neutralizing and protective antibodies directed against vaccinia virus envelope antigens. Virology 254:71–80
    [Google Scholar]
  11. Gong S. C., Lai C. F., Esteban M. 1990; Vaccinia virus induces cell fusion at acid pH and this activity is mediated by the N-terminus of the 14-kDa virus envelope protein. Virology 178:81–91
    [Google Scholar]
  12. Gordon J., Mohandas A., Wilton S., Dales S. 1991; A prominent antigenic surface polypeptide involved in the biogenesis and function of the vaccinia virus envelope. Virology 181:671–686
    [Google Scholar]
  13. Hiller G., Weber K. 1985; Golgi-derived membranes that contain an acylated viral polypeptide are used for vaccinia virus envelopment. Journal of Virology 55:651–659
    [Google Scholar]
  14. Hooper J. W., Custer D. M., Schmaljohn C. S., Schmaljohn A. L. 2000; DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge. Virology 266:329–339
    [Google Scholar]
  15. Hsiao J. C., Chung C. S., Chang W. 1999; Vaccinia virus envelope D8L protein binds to cell surface chondroitin sulfate and mediates the adsorption of intracellular mature virions to cells. Journal of Virology 73:8750–8761
    [Google Scholar]
  16. Ichihashi Y. 1996; Extracellular enveloped vaccinia virus escapes neutralization. Virology 217:478–485
    [Google Scholar]
  17. Kempe C. H. 1960; Studies on smallpox and complications of smallpox vaccination. Pediatrics 20:176–189
    [Google Scholar]
  18. Lai C. F., Gong S. C., Esteban M. 1991; The purified 14-kilodalton envelope protein of vaccinia virus produced in Escherichia coli induces virus immunity in animals. Journal of Virology 65:5631–5635
    [Google Scholar]
  19. Law M., Smith G. L. 2001; Antibody neutralization of the extracellular enveloped form of vaccinia virus. Virology 280:132–142
    [Google Scholar]
  20. Moss B. 1996; Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proceedings of the National Academy of Sciences, USA 93:11341–11348
    [Google Scholar]
  21. Mukinda V. B., Mwema G., Kilundu M., Heymann D. L., Khan A. S., Esposito J. J. 1997; Re-emergence of human monkeypox in Zaire in 1996. Lancet 349:1449–1450
    [Google Scholar]
  22. Ramírez J. C., Gherardi M. M., Esteban M. 2000; Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. Journal of Virology 74:923–933
    [Google Scholar]
  23. Rodríguez J. F., Smith G. L. 1990; IPTG-dependent vaccinia virus: identification of a virus protein enabling virion envelopment by Golgi membrane and egress. Nucleic Acids Research 18:5347–5351
    [Google Scholar]
  24. Rodríguez J. F., Janeczko R., Esteban M. 1985; Isolation and characterization of neutralizing monoclonal antibodies to vaccinia virus. Journal of Virology 56:482–488
    [Google Scholar]
  25. Rodríguez J. F., Paez E., Esteban M. 1987; A 14,000-Mr envelope protein of vaccinia virus is involved in cell fusion and forms covalently linked trimers. Journal of Virology 61:395–404
    [Google Scholar]
  26. Rodríguez J. F., Rodríguez D., Rodríguez J. R., McGowan E. B., Esteban M. 1988; Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals. Proceedings of the National Academy of Sciences, USA 85:1667–1671
    [Google Scholar]
  27. Rodríguez D., Rodríguez J.-R., Esteban M. 1993; The vaccinia virus 14-kilodalton fusion protein forms a stable complex with the processed protein encoded by the vaccinia virus A17L gene. Journal of Virology 67:3435–3440
    [Google Scholar]
  28. Shchelkunov S. N., Massung R. F., Esposito J. J. 1995; Comparison of the genome DNA sequences of Bangladesh-1975 and India-1967 variola viruses. Virus Research 36:107–118
    [Google Scholar]
  29. Smith G. L., Vanderplasschen A. 1998; Extracellular enveloped vaccinia virus. Entry, egress, and evasion. Advances in Experimental Medicine and Biology 440:395–414
    [Google Scholar]
  30. Sodeik B., Cudmore S., Ericsson M., Esteban M., Niles E. G., Griffiths G. 1995; Assembly of vaccinia virus: incorporation of p14 and p32 into the membrane of the intracellular mature virus. Journal of Virology 69:3560–3574
    [Google Scholar]
  31. Turner G. S., Squires E. J. 1971; Inactivated smallpox vaccine: immunogenicity of inactivated intracellular and extracellular vaccinia virus. Journal of General Virology 13:19–25
    [Google Scholar]
  32. Vanderplasschen A., Hollinshead M., Smith G. L. 1997; Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation. Journal of General Virology 78:2041–2048
    [Google Scholar]
  33. Vázquez M.-I., Esteban M. 1999; Identification of functional domains in the 14-kilodalton envelope protein (A27L) of vaccinia virus. Journal of Virology 73:9098–9109
    [Google Scholar]
  34. Vázquez M.-I., Rivas G., Cregut D., Serrano L., Esteban M. 1998; The vaccinia virus 14-kilodalton (A27L) fusion protein forms a triple coiled-coil structure and interacts with the 21-kilodalton (A17L) virus membrane protein through a C-terminal α-helix. Journal of Virology 72:10126–10137
    [Google Scholar]
  35. WHO 1980; The Global Eradication of Smallpox. Final Report of the Global Commission for the Certification of Smallpox Eradication . History of International Public Health no: 4 Geneva: World Health Organization;
    [Google Scholar]
  36. Wolffe E. J., Vijaya S., Moss B. 1995; A myristylated membrane protein encoded by the vaccinia virus L1R open reading frame is the target of potent neutralizing monoclonal antibodies. Virology 211:53–63
    [Google Scholar]
  37. Zinkernagel R. M., Ehl S., Aichele P., Oehen S., Kündig T., Hengartner H. 1997; Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity. Immunological Reviews 156:199–209
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-83-5-1059
Loading
/content/journal/jgv/10.1099/0022-1317-83-5-1059
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error